Via practica 3/2021

Diabetes mellitus and antiplatelet treatment: New antiplatelet therapy in diabetic patients with acute coronary syndromes

Acute coronary syndromes (ACS) with ST-segment elevation (STEMI) and without persistent ST-segment elevation based on the electrocardiogram (ekg), are life-threatening clinical conditions, much more with diabetes mellitus (DM) patients. Diabetic patients have generally higher risk for cardiovascular disease. DM is a disease with hypercoagulation – prothrombotic state including endothelial dysfunction and platelet hyper-reactivity. Arterial thromboembolic events are more frequent in diabetic patients versus patients without DM. ACS require precise diagnostic strategies, stratification risk between ischemic versus bleeding complications, but also quick antithrombotic (antiplatelet and anticoagulation) therapy with high efficiency clinical benefit and safety. In our paper, we would like to inform general physicians about current, new, not easy antiplatelet therapy in diabetic patients with ACS.

Keywords: diabetes mellitus, antiplatelet therapy, acute coronary syndrome